Immunotherapy increases survival in Hodgkin’s Lymphoma

Immunotherapy increases survival in Hodgkin’s Lymphoma

In new research adding Immunotherapy drug Nivolumab to chemotherapy for classic Hodgkin’s Lymphoma increases survival to 92% after two years, and avoided the need for radiotherapy. 

 

Standard of Care currently involves chemotherapy plus brentuximab vedotin, and radiotherapy. The chemotherapy drugs are doxorubicin, vinblastine, and dacarbazine (AVD). Often radiotherapy is added, which can cause new cancers later in life.

Wilmot Cancer Institute Director Jonathan Friedberg, MD, MMSc, at the University of Rochester Medical Center, led the study published in the New England Journal of Medicine October 17th 2024, which included participants from Medical centres across the USA.

994 patients were recruited into the 3 Phase trial and randomly assigned to either the current ‘Standard of Care’ or Nivolumab (a PD-1 immunotherapy) plus AVD chemotherapy.

The mean age of patients was 30, ranging from children over the age of 12 to adults of 60+ years.

After two years of follow-up, 92 percent of the immunotherapy group had survived and saw no progression of their disease, versus 83 percent in the standard care group. Radiotherapy was only used with 7 individuals.

The use of immunotherapy and the omission of radiotherapy are both thought to be very important as younger individuals having Classic Hodgkin’s Lymphoma treatment currently can go on to develop other cancers. Friedberg was highly hopeful that the use of immunotherapy drug Nivolumab would stop this happening.

Go to. Lymphoma - research review

******

References

  1. Herrera, A. F., et al. (2024) Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. New England Journal of Medicine. doi.org/10.1056/NEJMoa2405888 .

 

 


   .

  Approved by the Medical Board.  Click Here

 


   .

2024 Research
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Chris'
Newsletter

Join Chris' NewsletterSignup today for free and be the first to get notified on new updates.